{
  "metadata": {
    "analysis_version": "2.0_enhanced",
    "analysis_date": "2025-09-21T16:46:17.979300",
    "analysis_time_seconds": 8.024858713150024,
    "total_analyzed": 5,
    "undervalued_count": 2
  },
  "top_recommendations": [
    {
      "symbol": "207940",
      "name": "삼성바이오로직스",
      "enhanced_score": 34.832142857142856,
      "enhanced_grade": "D",
      "market_cap": 732380.0,
      "current_price": 1024000.0,
      "price_position": 38.741721854304636,
      "basic_result": "AnalysisResult(symbol='207940', name='삼성바이오로직스', status=<AnalysisStatus.SUCCESS: 'success'>, enhanced_score=34.832142857142856, enhanced_grade='D', market_cap=732380.0, current_price=1024000.0, price_position=38.741721854304636, risk_score=None, financial_data={'roe': 12.44, 'roa': 8.121164642903773, 'debt_ratio': 53.18, 'equity_ratio': 46.82, 'revenue_growth_rate': 23.02, 'operating_income_growth_rate': 46.73, 'net_income_growth_rate': 40.73, 'net_profit_margin': 27.04, 'gross_profit_margin': 56.09, 'profitability_grade': '우수', 'current_ratio': 156.67}, opinion_analysis={'symbol': '207940', 'analysis_period': '30일', 'total_opinions': 3, 'status': 'success', 'summary': InvestmentOpinionSummary(symbol='207940', total_opinions=3, buy_opinions=3, hold_opinions=0, sell_opinions=0, avg_target_price=0, max_target_price=0, min_target_price=0, avg_upside=0, most_recent_date='20250724', opinion_trend='상향'), 'detailed_analysis': {'opinion_distribution': {'BUY': 2, '매수': 1}, 'daily_opinion_count': {'20250724': 2, '20250625': 1}, 'recent_changes': 0, 'most_active_date': '20250724', 'total_brokerages': 3}, 'trend_analysis': {'sentiment_trend': '데이터 부족', 'target_price_trend': '데이터 부족', 'opinion_change_frequency': 0.0}, 'consensus_analysis': {'consensus_score': 1.0, 'consensus_level': '강한 매수', 'sample_size': 3}, 'target_price_analysis': {'status': 'no_data'}, 'brokerage_analysis': {'total_brokerages': 3, 'top_brokerages': [('하나증권', 1), ('미래에셋', 1), ('IM증권', 1)], 'brokerage_avg_targets': {}, 'concentration_ratio': 33.33333333333333}}, estimate_analysis={'symbol': '207940', 'status': 'success', 'summary': EstimatePerformanceSummary(symbol='A207940', name='삼성바이오로직스', current_price=0.0, change_rate=0.0, latest_revenue=30013.0, latest_revenue_growth=914.0, latest_operating_profit=9836.0, latest_operating_profit_growth=831.0, latest_net_profit=7981.0, latest_net_profit_growth=1028.0, latest_eps=114420.0, latest_per=718.0, latest_roe=114.0, latest_ev_ebitda=447.0, revenue_trend='하락', profit_trend='하락', eps_trend='하락', data_quality_score=1.0, latest_update_date='2022.12'), 'detailed_analysis': {'data_completeness': {'rate': 100.0, 'available_indicators': 6, 'total_indicators': 6, 'grade': 'A'}, 'revenue_analysis': {'latest_value': 30013.0, 'growth_rate': 914.0, 'data_points': 5}, 'profit_analysis': {'operating_profit': 9836.0, 'net_profit': 7981.0, 'operating_growth': 831.0, 'net_growth': 1028.0}, 'investment_metrics': {'eps': 114420.0, 'per': 718.0, 'roe': 114.0, 'ev_ebitda': 447.0, 'debt_ratio': 846.0, 'interest_coverage': 154.0}, 'settlement_periods': ['2022.12', '2023.12', '2024.12', '2025.12E', '2026.12E']}, 'trend_analysis': {'revenue': {'direction': '강한 하락', 'strength': 0.0, 'volatility': 25.125606555290215, 'data_points': 5}, 'operating_profit': {'direction': '강한 하락', 'strength': 0.0, 'volatility': 25.606819577859575, 'data_points': 5}, 'net_profit': {'direction': '강한 하락', 'strength': 0.0, 'volatility': 25.805633553905654, 'data_points': 5}, 'eps': {'direction': '강한 하락', 'strength': 0.0, 'volatility': 25.403459381502735, 'data_points': 5}, 'roe': {'direction': '상승', 'strength': 65.71428571428571, 'volatility': 10.710310163653194, 'data_points': 5}}, 'financial_health': {'health_score': 50, 'health_grade': 'C', 'factors': ['ROE 우수 (114.0%)', '부채비율 높음 (846.0%)', '이자보상배율 우수 (154.0배)'], 'max_score': 100}, 'valuation_analysis': {'per': {'value': 718.0, 'grade': 'F', 'interpretation': '매우 고평가'}, 'ev_ebitda': {'value': 447.0, 'grade': 'F', 'interpretation': '매우 고평가'}, 'overall_score': 10, 'overall_grade': 'F'}, 'growth_analysis': {'revenue_growth': {'value': 914.0, 'grade': 'A', 'interpretation': '매우 높은 성장'}, 'profit_growth': {'value': 831.0, 'grade': 'A', 'interpretation': '매우 높은 성장'}, 'eps_growth': {'value': 947.0, 'grade': 'A', 'interpretation': '매우 높은 성장'}}, 'quality_analysis': {'quality_score': 1.0, 'quality_grade': 'A', 'completeness': {'rate': 100.0, 'available_indicators': 6, 'total_indicators': 6, 'grade': 'A'}, 'consistency': {'score': 1.0, 'grade': 'A'}, 'latest_update': '2022.12'}}, integrated_analysis={'symbol': '207940', 'analysis_timestamp': '2025-09-21T16:46:12.952438', 'opinion_analysis': {'symbol': '207940', 'analysis_period': '30일', 'total_opinions': 3, 'status': 'success', 'summary': InvestmentOpinionSummary(symbol='207940', total_opinions=3, buy_opinions=3, hold_opinions=0, sell_opinions=0, avg_target_price=0, max_target_price=0, min_target_price=0, avg_upside=0, most_recent_date='20250724', opinion_trend='상향'), 'detailed_analysis': {'opinion_distribution': {'BUY': 2, '매수': 1}, 'daily_opinion_count': {'20250724': 2, '20250625': 1}, 'recent_changes': 0, 'most_active_date': '20250724', 'total_brokerages': 3}, 'trend_analysis': {'sentiment_trend': '데이터 부족', 'target_price_trend': '데이터 부족', 'opinion_change_frequency': 0.0}, 'consensus_analysis': {'consensus_score': 1.0, 'consensus_level': '강한 매수', 'sample_size': 3}, 'target_price_analysis': {'status': 'no_data'}, 'brokerage_analysis': {'total_brokerages': 3, 'top_brokerages': [('하나증권', 1), ('미래에셋', 1), ('IM증권', 1)], 'brokerage_avg_targets': {}, 'concentration_ratio': 33.33333333333333}}, 'estimate_analysis': {'symbol': '207940', 'status': 'success', 'summary': EstimatePerformanceSummary(symbol='A207940', name='삼성바이오로직스', current_price=0.0, change_rate=0.0, latest_revenue=30013.0, latest_revenue_growth=914.0, latest_operating_profit=9836.0, latest_operating_profit_growth=831.0, latest_net_profit=7981.0, latest_net_profit_growth=1028.0, latest_eps=114420.0, latest_per=718.0, latest_roe=114.0, latest_ev_ebitda=447.0, revenue_trend='하락', profit_trend='하락', eps_trend='하락', data_quality_score=1.0, latest_update_date='2022.12'), 'detailed_analysis': {'data_completeness': {'rate': 100.0, 'available_indicators': 6, 'total_indicators': 6, 'grade': 'A'}, 'revenue_analysis': {'latest_value': 30013.0, 'growth_rate': 914.0, 'data_points': 5}, 'profit_analysis': {'operating_profit': 9836.0, 'net_profit': 7981.0, 'operating_growth': 831.0, 'net_growth': 1028.0}, 'investment_metrics': {'eps': 114420.0, 'per': 718.0, 'roe': 114.0, 'ev_ebitda': 447.0, 'debt_ratio': 846.0, 'interest_coverage': 154.0}, 'settlement_periods': ['2022.12', '2023.12', '2024.12', '2025.12E', '2026.12E']}, 'trend_analysis': {'revenue': {'direction': '강한 하락', 'strength': 0.0, 'volatility': 25.125606555290215, 'data_points': 5}, 'operating_profit': {'direction': '강한 하락', 'strength': 0.0, 'volatility': 25.606819577859575, 'data_points': 5}, 'net_profit': {'direction': '강한 하락', 'strength': 0.0, 'volatility': 25.805633553905654, 'data_points': 5}, 'eps': {'direction': '강한 하락', 'strength': 0.0, 'volatility': 25.403459381502735, 'data_points': 5}, 'roe': {'direction': '상승', 'strength': 65.71428571428571, 'volatility': 10.710310163653194, 'data_points': 5}}, 'financial_health': {'health_score': 50, 'health_grade': 'C', 'factors': ['ROE 우수 (114.0%)', '부채비율 높음 (846.0%)', '이자보상배율 우수 (154.0배)'], 'max_score': 100}, 'valuation_analysis': {'per': {'value': 718.0, 'grade': 'F', 'interpretation': '매우 고평가'}, 'ev_ebitda': {'value': 447.0, 'grade': 'F', 'interpretation': '매우 고평가'}, 'overall_score': 10, 'overall_grade': 'F'}, 'growth_analysis': {'revenue_growth': {'value': 914.0, 'grade': 'A', 'interpretation': '매우 높은 성장'}, 'profit_growth': {'value': 831.0, 'grade': 'A', 'interpretation': '매우 높은 성장'}, 'eps_growth': {'value': 947.0, 'grade': 'A', 'interpretation': '매우 높은 성장'}}, 'quality_analysis': {'quality_score': 1.0, 'quality_grade': 'A', 'completeness': {'rate': 100.0, 'available_indicators': 6, 'total_indicators': 6, 'grade': 'A'}, 'consistency': {'score': 1.0, 'grade': 'A'}, 'latest_update': '2022.12'}}, 'integrated_score': 72.0, 'integrated_grade': 'B', 'investment_recommendation': '적극 검토 추천', 'risk_assessment': '낮음', 'total_opinions': 3, 'buy_opinions': 3, 'hold_opinions': 0, 'sell_opinions': 0, 'consensus_score': 1.0, 'avg_target_price': 0, 'avg_upside': 0, 'opinion_trend': '상향', 'current_price': 0.0, 'latest_revenue': 30013.0, 'latest_revenue_growth': 914.0, 'latest_operating_profit': 9836.0, 'latest_operating_profit_growth': 831.0, 'latest_eps': 114420.0, 'latest_per': 718.0, 'latest_roe': 114.0, 'revenue_trend': '하락', 'profit_trend': '하락', 'eps_trend': '하락', 'data_quality_score': 1.0, 'financial_health_score': 50, 'valuation_score': 10}, risk_analysis={}, score_breakdown={'투자의견': 0.0, '추정실적': 0.0, '재무비율': 19.83214285714286, '성장성': 10.0, '규모': 5.0, '가격위치': 0.0}, error=None, price_data={'current_price': 1024000.0, 'price_change': -5000.0, 'price_change_rate': -0.49, 'volume': 91201.0, 'per': 67.28, 'pbr': 6.68, 'eps': 15221.0, 'bps': 153212.0, 'market_cap': 72882200000000.0, 'w52_high': 1209000.0, 'w52_low': 907000.0})",
      "enhanced_result": "AnalysisResult(symbol='207940', name='삼성바이오로직스', status=<AnalysisStatus.SUCCESS: 'success'>, enhanced_score=34.832142857142856, enhanced_grade='D', market_cap=732380.0, current_price=1024000.0, price_position=38.741721854304636, risk_score=None, financial_data={'roe': 12.44, 'roa': 8.121164642903773, 'debt_ratio': 53.18, 'equity_ratio': 46.82, 'revenue_growth_rate': 23.02, 'operating_income_growth_rate': 46.73, 'net_income_growth_rate': 40.73, 'net_profit_margin': 27.04, 'gross_profit_margin': 56.09, 'profitability_grade': '우수', 'current_ratio': 156.67}, opinion_analysis={'symbol': '207940', 'analysis_period': '30일', 'total_opinions': 3, 'status': 'success', 'summary': InvestmentOpinionSummary(symbol='207940', total_opinions=3, buy_opinions=3, hold_opinions=0, sell_opinions=0, avg_target_price=0, max_target_price=0, min_target_price=0, avg_upside=0, most_recent_date='20250724', opinion_trend='상향'), 'detailed_analysis': {'opinion_distribution': {'BUY': 2, '매수': 1}, 'daily_opinion_count': {'20250724': 2, '20250625': 1}, 'recent_changes': 0, 'most_active_date': '20250724', 'total_brokerages': 3}, 'trend_analysis': {'sentiment_trend': '데이터 부족', 'target_price_trend': '데이터 부족', 'opinion_change_frequency': 0.0}, 'consensus_analysis': {'consensus_score': 1.0, 'consensus_level': '강한 매수', 'sample_size': 3}, 'target_price_analysis': {'status': 'no_data'}, 'brokerage_analysis': {'total_brokerages': 3, 'top_brokerages': [('하나증권', 1), ('미래에셋', 1), ('IM증권', 1)], 'brokerage_avg_targets': {}, 'concentration_ratio': 33.33333333333333}}, estimate_analysis={'symbol': '207940', 'status': 'success', 'summary': EstimatePerformanceSummary(symbol='A207940', name='삼성바이오로직스', current_price=0.0, change_rate=0.0, latest_revenue=30013.0, latest_revenue_growth=914.0, latest_operating_profit=9836.0, latest_operating_profit_growth=831.0, latest_net_profit=7981.0, latest_net_profit_growth=1028.0, latest_eps=114420.0, latest_per=718.0, latest_roe=114.0, latest_ev_ebitda=447.0, revenue_trend='하락', profit_trend='하락', eps_trend='하락', data_quality_score=1.0, latest_update_date='2022.12'), 'detailed_analysis': {'data_completeness': {'rate': 100.0, 'available_indicators': 6, 'total_indicators': 6, 'grade': 'A'}, 'revenue_analysis': {'latest_value': 30013.0, 'growth_rate': 914.0, 'data_points': 5}, 'profit_analysis': {'operating_profit': 9836.0, 'net_profit': 7981.0, 'operating_growth': 831.0, 'net_growth': 1028.0}, 'investment_metrics': {'eps': 114420.0, 'per': 718.0, 'roe': 114.0, 'ev_ebitda': 447.0, 'debt_ratio': 846.0, 'interest_coverage': 154.0}, 'settlement_periods': ['2022.12', '2023.12', '2024.12', '2025.12E', '2026.12E']}, 'trend_analysis': {'revenue': {'direction': '강한 하락', 'strength': 0.0, 'volatility': 25.125606555290215, 'data_points': 5}, 'operating_profit': {'direction': '강한 하락', 'strength': 0.0, 'volatility': 25.606819577859575, 'data_points': 5}, 'net_profit': {'direction': '강한 하락', 'strength': 0.0, 'volatility': 25.805633553905654, 'data_points': 5}, 'eps': {'direction': '강한 하락', 'strength': 0.0, 'volatility': 25.403459381502735, 'data_points': 5}, 'roe': {'direction': '상승', 'strength': 65.71428571428571, 'volatility': 10.710310163653194, 'data_points': 5}}, 'financial_health': {'health_score': 50, 'health_grade': 'C', 'factors': ['ROE 우수 (114.0%)', '부채비율 높음 (846.0%)', '이자보상배율 우수 (154.0배)'], 'max_score': 100}, 'valuation_analysis': {'per': {'value': 718.0, 'grade': 'F', 'interpretation': '매우 고평가'}, 'ev_ebitda': {'value': 447.0, 'grade': 'F', 'interpretation': '매우 고평가'}, 'overall_score': 10, 'overall_grade': 'F'}, 'growth_analysis': {'revenue_growth': {'value': 914.0, 'grade': 'A', 'interpretation': '매우 높은 성장'}, 'profit_growth': {'value': 831.0, 'grade': 'A', 'interpretation': '매우 높은 성장'}, 'eps_growth': {'value': 947.0, 'grade': 'A', 'interpretation': '매우 높은 성장'}}, 'quality_analysis': {'quality_score': 1.0, 'quality_grade': 'A', 'completeness': {'rate': 100.0, 'available_indicators': 6, 'total_indicators': 6, 'grade': 'A'}, 'consistency': {'score': 1.0, 'grade': 'A'}, 'latest_update': '2022.12'}}, integrated_analysis={'symbol': '207940', 'analysis_timestamp': '2025-09-21T16:46:12.952438', 'opinion_analysis': {'symbol': '207940', 'analysis_period': '30일', 'total_opinions': 3, 'status': 'success', 'summary': InvestmentOpinionSummary(symbol='207940', total_opinions=3, buy_opinions=3, hold_opinions=0, sell_opinions=0, avg_target_price=0, max_target_price=0, min_target_price=0, avg_upside=0, most_recent_date='20250724', opinion_trend='상향'), 'detailed_analysis': {'opinion_distribution': {'BUY': 2, '매수': 1}, 'daily_opinion_count': {'20250724': 2, '20250625': 1}, 'recent_changes': 0, 'most_active_date': '20250724', 'total_brokerages': 3}, 'trend_analysis': {'sentiment_trend': '데이터 부족', 'target_price_trend': '데이터 부족', 'opinion_change_frequency': 0.0}, 'consensus_analysis': {'consensus_score': 1.0, 'consensus_level': '강한 매수', 'sample_size': 3}, 'target_price_analysis': {'status': 'no_data'}, 'brokerage_analysis': {'total_brokerages': 3, 'top_brokerages': [('하나증권', 1), ('미래에셋', 1), ('IM증권', 1)], 'brokerage_avg_targets': {}, 'concentration_ratio': 33.33333333333333}}, 'estimate_analysis': {'symbol': '207940', 'status': 'success', 'summary': EstimatePerformanceSummary(symbol='A207940', name='삼성바이오로직스', current_price=0.0, change_rate=0.0, latest_revenue=30013.0, latest_revenue_growth=914.0, latest_operating_profit=9836.0, latest_operating_profit_growth=831.0, latest_net_profit=7981.0, latest_net_profit_growth=1028.0, latest_eps=114420.0, latest_per=718.0, latest_roe=114.0, latest_ev_ebitda=447.0, revenue_trend='하락', profit_trend='하락', eps_trend='하락', data_quality_score=1.0, latest_update_date='2022.12'), 'detailed_analysis': {'data_completeness': {'rate': 100.0, 'available_indicators': 6, 'total_indicators': 6, 'grade': 'A'}, 'revenue_analysis': {'latest_value': 30013.0, 'growth_rate': 914.0, 'data_points': 5}, 'profit_analysis': {'operating_profit': 9836.0, 'net_profit': 7981.0, 'operating_growth': 831.0, 'net_growth': 1028.0}, 'investment_metrics': {'eps': 114420.0, 'per': 718.0, 'roe': 114.0, 'ev_ebitda': 447.0, 'debt_ratio': 846.0, 'interest_coverage': 154.0}, 'settlement_periods': ['2022.12', '2023.12', '2024.12', '2025.12E', '2026.12E']}, 'trend_analysis': {'revenue': {'direction': '강한 하락', 'strength': 0.0, 'volatility': 25.125606555290215, 'data_points': 5}, 'operating_profit': {'direction': '강한 하락', 'strength': 0.0, 'volatility': 25.606819577859575, 'data_points': 5}, 'net_profit': {'direction': '강한 하락', 'strength': 0.0, 'volatility': 25.805633553905654, 'data_points': 5}, 'eps': {'direction': '강한 하락', 'strength': 0.0, 'volatility': 25.403459381502735, 'data_points': 5}, 'roe': {'direction': '상승', 'strength': 65.71428571428571, 'volatility': 10.710310163653194, 'data_points': 5}}, 'financial_health': {'health_score': 50, 'health_grade': 'C', 'factors': ['ROE 우수 (114.0%)', '부채비율 높음 (846.0%)', '이자보상배율 우수 (154.0배)'], 'max_score': 100}, 'valuation_analysis': {'per': {'value': 718.0, 'grade': 'F', 'interpretation': '매우 고평가'}, 'ev_ebitda': {'value': 447.0, 'grade': 'F', 'interpretation': '매우 고평가'}, 'overall_score': 10, 'overall_grade': 'F'}, 'growth_analysis': {'revenue_growth': {'value': 914.0, 'grade': 'A', 'interpretation': '매우 높은 성장'}, 'profit_growth': {'value': 831.0, 'grade': 'A', 'interpretation': '매우 높은 성장'}, 'eps_growth': {'value': 947.0, 'grade': 'A', 'interpretation': '매우 높은 성장'}}, 'quality_analysis': {'quality_score': 1.0, 'quality_grade': 'A', 'completeness': {'rate': 100.0, 'available_indicators': 6, 'total_indicators': 6, 'grade': 'A'}, 'consistency': {'score': 1.0, 'grade': 'A'}, 'latest_update': '2022.12'}}, 'integrated_score': 72.0, 'integrated_grade': 'B', 'investment_recommendation': '적극 검토 추천', 'risk_assessment': '낮음', 'total_opinions': 3, 'buy_opinions': 3, 'hold_opinions': 0, 'sell_opinions': 0, 'consensus_score': 1.0, 'avg_target_price': 0, 'avg_upside': 0, 'opinion_trend': '상향', 'current_price': 0.0, 'latest_revenue': 30013.0, 'latest_revenue_growth': 914.0, 'latest_operating_profit': 9836.0, 'latest_operating_profit_growth': 831.0, 'latest_eps': 114420.0, 'latest_per': 718.0, 'latest_roe': 114.0, 'revenue_trend': '하락', 'profit_trend': '하락', 'eps_trend': '하락', 'data_quality_score': 1.0, 'financial_health_score': 50, 'valuation_score': 10}, risk_analysis={}, score_breakdown={'투자의견': 0.0, '추정실적': 0.0, '재무비율': 19.83214285714286, '성장성': 10.0, '규모': 5.0, '가격위치': 0.0}, error=None, price_data={'current_price': 1024000.0, 'price_change': -5000.0, 'price_change_rate': -0.49, 'volume': 91201.0, 'per': 67.28, 'pbr': 6.68, 'eps': 15221.0, 'bps': 153212.0, 'market_cap': 72882200000000.0, 'w52_high': 1209000.0, 'w52_low': 907000.0})"
    },
    {
      "symbol": "000660",
      "name": "SK하이닉스",
      "enhanced_score": 27.064285714285717,
      "enhanced_grade": "D",
      "market_cap": 2569848.0,
      "current_price": 353000.0,
      "price_position": 96.7487227124942,
      "basic_result": "AnalysisResult(symbol='000660', name='SK하이닉스', status=<AnalysisStatus.SUCCESS: 'success'>, enhanced_score=27.064285714285717, enhanced_grade='D', market_cap=2569848.0, current_price=353000.0, price_position=96.7487227124942, risk_score=None, financial_data={'roe': 37.52, 'roa': 25.32910281509485, 'debt_ratio': 48.13, 'equity_ratio': 51.87, 'revenue_growth_rate': 38.19, 'operating_income_growth_rate': 99.33, 'net_income_growth_rate': 150.2, 'net_profit_margin': 37.88, 'gross_profit_margin': 55.39, 'profitability_grade': '우수', 'current_ratio': 178.5}, opinion_analysis={'symbol': '000660', 'analysis_period': '30일', 'total_opinions': 6, 'status': 'success', 'summary': InvestmentOpinionSummary(symbol='000660', total_opinions=6, buy_opinions=6, hold_opinions=0, sell_opinions=0, avg_target_price=411666.67, max_target_price=480000.0, min_target_price=380000.0, avg_upside=25.27, most_recent_date='20250918', opinion_trend='상향'), 'detailed_analysis': {'opinion_distribution': {'BUY': 4, '매수': 2}, 'daily_opinion_count': {'20250918': 1, '20250917': 2, '20250916': 1, '20250915': 1, '20250910': 1}, 'recent_changes': 0, 'most_active_date': '20250918', 'total_brokerages': 6}, 'trend_analysis': {'sentiment_trend': '보합', 'target_price_trend': '상승', 'opinion_change_frequency': 0.0}, 'consensus_analysis': {'consensus_score': 1.0, 'consensus_level': '강한 매수', 'sample_size': 6}, 'target_price_analysis': {'avg_target_price': 411666.67, 'max_target_price': 480000.0, 'min_target_price': 380000.0, 'price_range': 100000.0, 'avg_upside_potential': 42.94, 'target_count': 6, 'coverage_rate': 100.0}, 'brokerage_analysis': {'total_brokerages': 6, 'top_brokerages': [('대신', 1), ('SK', 1), ('현대차', 1), ('NH투자', 1), ('IM증권', 1)], 'brokerage_avg_targets': {'대신': 400000.0, 'SK': 480000.0, '현대차': 405000.0, 'NH투자': 395000.0, 'IM증권': 380000.0, '한국투자': 410000.0}, 'concentration_ratio': 16.666666666666664}}, estimate_analysis={'symbol': '000660', 'status': 'success', 'summary': EstimatePerformanceSummary(symbol='A000660', name='에스케이하이닉스', current_price=0.0, change_rate=0.0, latest_revenue=446216.0, latest_revenue_growth=38.0, latest_operating_profit=68094.0, latest_operating_profit_growth=-451.0, latest_net_profit=22296.0, latest_net_profit_growth=-768.0, latest_eps=32420.0, latest_per=231.0, latest_roe=36.0, latest_ev_ebitda=34.0, revenue_trend='상승', profit_trend='상승', eps_trend='상승', data_quality_score=1.0, latest_update_date='2022.12'), 'detailed_analysis': {'data_completeness': {'rate': 100.0, 'available_indicators': 6, 'total_indicators': 6, 'grade': 'A'}, 'revenue_analysis': {'latest_value': 446216.0, 'growth_rate': 38.0, 'data_points': 5}, 'profit_analysis': {'operating_profit': 68094.0, 'net_profit': 22296.0, 'operating_growth': -451.0, 'net_growth': -768.0}, 'investment_metrics': {'eps': 32420.0, 'per': 231.0, 'roe': 36.0, 'ev_ebitda': 34.0, 'debt_ratio': 641.0, 'interest_coverage': 128.0}, 'settlement_periods': ['2022.12', '2023.12', '2024.12', '2025.12E', '2026.12E']}, 'trend_analysis': {'revenue': {'direction': '상승', 'strength': 15.156869036950294, 'volatility': 41.6085084543022, 'data_points': 5}, 'operating_profit': {'direction': '상승', 'strength': 23.23441192873568, 'volatility': 95.49386740240358, 'data_points': 5}, 'net_profit': {'direction': '상승', 'strength': 19.532238871256336, 'volatility': 108.20659300130065, 'data_points': 5}, 'eps': {'direction': '상승', 'strength': 19.591764946356165, 'volatility': 108.21088773168226, 'data_points': 5}, 'roe': {'direction': '상승', 'strength': 34.47037701974865, 'volatility': 113.04619349020601, 'data_points': 5}}, 'financial_health': {'health_score': 50, 'health_grade': 'C', 'factors': ['ROE 우수 (36.0%)', '부채비율 높음 (641.0%)', '이자보상배율 우수 (128.0배)'], 'max_score': 100}, 'valuation_analysis': {'per': {'value': 231.0, 'grade': 'F', 'interpretation': '매우 고평가'}, 'ev_ebitda': {'value': 34.0, 'grade': 'F', 'interpretation': '매우 고평가'}, 'overall_score': 10, 'overall_grade': 'F'}, 'growth_analysis': {'revenue_growth': {'value': 38.0, 'grade': 'A', 'interpretation': '매우 높은 성장'}, 'profit_growth': {'value': -451.0, 'grade': 'F', 'interpretation': '성장 정체'}, 'eps_growth': {'value': -768.0, 'grade': 'F', 'interpretation': '성장 정체'}}, 'quality_analysis': {'quality_score': 1.0, 'quality_grade': 'A', 'completeness': {'rate': 100.0, 'available_indicators': 6, 'total_indicators': 6, 'grade': 'A'}, 'consistency': {'score': 1.0, 'grade': 'A'}, 'latest_update': '2022.12'}}, integrated_analysis={'symbol': '000660', 'analysis_timestamp': '2025-09-21T16:46:17.856491', 'opinion_analysis': {'symbol': '000660', 'analysis_period': '30일', 'total_opinions': 6, 'status': 'success', 'summary': InvestmentOpinionSummary(symbol='000660', total_opinions=6, buy_opinions=6, hold_opinions=0, sell_opinions=0, avg_target_price=411666.67, max_target_price=480000.0, min_target_price=380000.0, avg_upside=25.27, most_recent_date='20250918', opinion_trend='상향'), 'detailed_analysis': {'opinion_distribution': {'BUY': 4, '매수': 2}, 'daily_opinion_count': {'20250918': 1, '20250917': 2, '20250916': 1, '20250915': 1, '20250910': 1}, 'recent_changes': 0, 'most_active_date': '20250918', 'total_brokerages': 6}, 'trend_analysis': {'sentiment_trend': '보합', 'target_price_trend': '상승', 'opinion_change_frequency': 0.0}, 'consensus_analysis': {'consensus_score': 1.0, 'consensus_level': '강한 매수', 'sample_size': 6}, 'target_price_analysis': {'avg_target_price': 411666.67, 'max_target_price': 480000.0, 'min_target_price': 380000.0, 'price_range': 100000.0, 'avg_upside_potential': 42.94, 'target_count': 6, 'coverage_rate': 100.0}, 'brokerage_analysis': {'total_brokerages': 6, 'top_brokerages': [('대신', 1), ('SK', 1), ('현대차', 1), ('NH투자', 1), ('IM증권', 1)], 'brokerage_avg_targets': {'대신': 400000.0, 'SK': 480000.0, '현대차': 405000.0, 'NH투자': 395000.0, 'IM증권': 380000.0, '한국투자': 410000.0}, 'concentration_ratio': 16.666666666666664}}, 'estimate_analysis': {'symbol': '000660', 'status': 'success', 'summary': EstimatePerformanceSummary(symbol='A000660', name='에스케이하이닉스', current_price=0.0, change_rate=0.0, latest_revenue=446216.0, latest_revenue_growth=38.0, latest_operating_profit=68094.0, latest_operating_profit_growth=-451.0, latest_net_profit=22296.0, latest_net_profit_growth=-768.0, latest_eps=32420.0, latest_per=231.0, latest_roe=36.0, latest_ev_ebitda=34.0, revenue_trend='상승', profit_trend='상승', eps_trend='상승', data_quality_score=1.0, latest_update_date='2022.12'), 'detailed_analysis': {'data_completeness': {'rate': 100.0, 'available_indicators': 6, 'total_indicators': 6, 'grade': 'A'}, 'revenue_analysis': {'latest_value': 446216.0, 'growth_rate': 38.0, 'data_points': 5}, 'profit_analysis': {'operating_profit': 68094.0, 'net_profit': 22296.0, 'operating_growth': -451.0, 'net_growth': -768.0}, 'investment_metrics': {'eps': 32420.0, 'per': 231.0, 'roe': 36.0, 'ev_ebitda': 34.0, 'debt_ratio': 641.0, 'interest_coverage': 128.0}, 'settlement_periods': ['2022.12', '2023.12', '2024.12', '2025.12E', '2026.12E']}, 'trend_analysis': {'revenue': {'direction': '상승', 'strength': 15.156869036950294, 'volatility': 41.6085084543022, 'data_points': 5}, 'operating_profit': {'direction': '상승', 'strength': 23.23441192873568, 'volatility': 95.49386740240358, 'data_points': 5}, 'net_profit': {'direction': '상승', 'strength': 19.532238871256336, 'volatility': 108.20659300130065, 'data_points': 5}, 'eps': {'direction': '상승', 'strength': 19.591764946356165, 'volatility': 108.21088773168226, 'data_points': 5}, 'roe': {'direction': '상승', 'strength': 34.47037701974865, 'volatility': 113.04619349020601, 'data_points': 5}}, 'financial_health': {'health_score': 50, 'health_grade': 'C', 'factors': ['ROE 우수 (36.0%)', '부채비율 높음 (641.0%)', '이자보상배율 우수 (128.0배)'], 'max_score': 100}, 'valuation_analysis': {'per': {'value': 231.0, 'grade': 'F', 'interpretation': '매우 고평가'}, 'ev_ebitda': {'value': 34.0, 'grade': 'F', 'interpretation': '매우 고평가'}, 'overall_score': 10, 'overall_grade': 'F'}, 'growth_analysis': {'revenue_growth': {'value': 38.0, 'grade': 'A', 'interpretation': '매우 높은 성장'}, 'profit_growth': {'value': -451.0, 'grade': 'F', 'interpretation': '성장 정체'}, 'eps_growth': {'value': -768.0, 'grade': 'F', 'interpretation': '성장 정체'}}, 'quality_analysis': {'quality_score': 1.0, 'quality_grade': 'A', 'completeness': {'rate': 100.0, 'available_indicators': 6, 'total_indicators': 6, 'grade': 'A'}, 'consistency': {'score': 1.0, 'grade': 'A'}, 'latest_update': '2022.12'}}, 'integrated_score': 72.0, 'integrated_grade': 'B', 'investment_recommendation': '적극 검토 추천', 'risk_assessment': '낮음', 'total_opinions': 6, 'buy_opinions': 6, 'hold_opinions': 0, 'sell_opinions': 0, 'consensus_score': 1.0, 'avg_target_price': 411666.67, 'avg_upside': 25.27, 'opinion_trend': '상향', 'current_price': 0.0, 'latest_revenue': 446216.0, 'latest_revenue_growth': 38.0, 'latest_operating_profit': 68094.0, 'latest_operating_profit_growth': -451.0, 'latest_eps': 32420.0, 'latest_per': 231.0, 'latest_roe': 36.0, 'revenue_trend': '상승', 'profit_trend': '상승', 'eps_trend': '상승', 'data_quality_score': 1.0, 'financial_health_score': 50, 'valuation_score': 10}, risk_analysis={}, score_breakdown={'투자의견': 0.0, '추정실적': 0.0, '재무비율': 27.064285714285717, '성장성': 10.0, '규모': 5.0, '가격위치': -15.0}, error=None, price_data={'current_price': 353000.0, 'price_change': 0.0, 'price_change_rate': 0.0, 'volume': 4385543.0, 'per': 12.99, 'pbr': 3.38, 'eps': 27182.0, 'bps': 104567.0, 'market_cap': 256984800000000.0, 'w52_high': 360000.0, 'w52_low': 144700.0})",
      "enhanced_result": "AnalysisResult(symbol='000660', name='SK하이닉스', status=<AnalysisStatus.SUCCESS: 'success'>, enhanced_score=27.064285714285717, enhanced_grade='D', market_cap=2569848.0, current_price=353000.0, price_position=96.7487227124942, risk_score=None, financial_data={'roe': 37.52, 'roa': 25.32910281509485, 'debt_ratio': 48.13, 'equity_ratio': 51.87, 'revenue_growth_rate': 38.19, 'operating_income_growth_rate': 99.33, 'net_income_growth_rate': 150.2, 'net_profit_margin': 37.88, 'gross_profit_margin': 55.39, 'profitability_grade': '우수', 'current_ratio': 178.5}, opinion_analysis={'symbol': '000660', 'analysis_period': '30일', 'total_opinions': 6, 'status': 'success', 'summary': InvestmentOpinionSummary(symbol='000660', total_opinions=6, buy_opinions=6, hold_opinions=0, sell_opinions=0, avg_target_price=411666.67, max_target_price=480000.0, min_target_price=380000.0, avg_upside=25.27, most_recent_date='20250918', opinion_trend='상향'), 'detailed_analysis': {'opinion_distribution': {'BUY': 4, '매수': 2}, 'daily_opinion_count': {'20250918': 1, '20250917': 2, '20250916': 1, '20250915': 1, '20250910': 1}, 'recent_changes': 0, 'most_active_date': '20250918', 'total_brokerages': 6}, 'trend_analysis': {'sentiment_trend': '보합', 'target_price_trend': '상승', 'opinion_change_frequency': 0.0}, 'consensus_analysis': {'consensus_score': 1.0, 'consensus_level': '강한 매수', 'sample_size': 6}, 'target_price_analysis': {'avg_target_price': 411666.67, 'max_target_price': 480000.0, 'min_target_price': 380000.0, 'price_range': 100000.0, 'avg_upside_potential': 42.94, 'target_count': 6, 'coverage_rate': 100.0}, 'brokerage_analysis': {'total_brokerages': 6, 'top_brokerages': [('대신', 1), ('SK', 1), ('현대차', 1), ('NH투자', 1), ('IM증권', 1)], 'brokerage_avg_targets': {'대신': 400000.0, 'SK': 480000.0, '현대차': 405000.0, 'NH투자': 395000.0, 'IM증권': 380000.0, '한국투자': 410000.0}, 'concentration_ratio': 16.666666666666664}}, estimate_analysis={'symbol': '000660', 'status': 'success', 'summary': EstimatePerformanceSummary(symbol='A000660', name='에스케이하이닉스', current_price=0.0, change_rate=0.0, latest_revenue=446216.0, latest_revenue_growth=38.0, latest_operating_profit=68094.0, latest_operating_profit_growth=-451.0, latest_net_profit=22296.0, latest_net_profit_growth=-768.0, latest_eps=32420.0, latest_per=231.0, latest_roe=36.0, latest_ev_ebitda=34.0, revenue_trend='상승', profit_trend='상승', eps_trend='상승', data_quality_score=1.0, latest_update_date='2022.12'), 'detailed_analysis': {'data_completeness': {'rate': 100.0, 'available_indicators': 6, 'total_indicators': 6, 'grade': 'A'}, 'revenue_analysis': {'latest_value': 446216.0, 'growth_rate': 38.0, 'data_points': 5}, 'profit_analysis': {'operating_profit': 68094.0, 'net_profit': 22296.0, 'operating_growth': -451.0, 'net_growth': -768.0}, 'investment_metrics': {'eps': 32420.0, 'per': 231.0, 'roe': 36.0, 'ev_ebitda': 34.0, 'debt_ratio': 641.0, 'interest_coverage': 128.0}, 'settlement_periods': ['2022.12', '2023.12', '2024.12', '2025.12E', '2026.12E']}, 'trend_analysis': {'revenue': {'direction': '상승', 'strength': 15.156869036950294, 'volatility': 41.6085084543022, 'data_points': 5}, 'operating_profit': {'direction': '상승', 'strength': 23.23441192873568, 'volatility': 95.49386740240358, 'data_points': 5}, 'net_profit': {'direction': '상승', 'strength': 19.532238871256336, 'volatility': 108.20659300130065, 'data_points': 5}, 'eps': {'direction': '상승', 'strength': 19.591764946356165, 'volatility': 108.21088773168226, 'data_points': 5}, 'roe': {'direction': '상승', 'strength': 34.47037701974865, 'volatility': 113.04619349020601, 'data_points': 5}}, 'financial_health': {'health_score': 50, 'health_grade': 'C', 'factors': ['ROE 우수 (36.0%)', '부채비율 높음 (641.0%)', '이자보상배율 우수 (128.0배)'], 'max_score': 100}, 'valuation_analysis': {'per': {'value': 231.0, 'grade': 'F', 'interpretation': '매우 고평가'}, 'ev_ebitda': {'value': 34.0, 'grade': 'F', 'interpretation': '매우 고평가'}, 'overall_score': 10, 'overall_grade': 'F'}, 'growth_analysis': {'revenue_growth': {'value': 38.0, 'grade': 'A', 'interpretation': '매우 높은 성장'}, 'profit_growth': {'value': -451.0, 'grade': 'F', 'interpretation': '성장 정체'}, 'eps_growth': {'value': -768.0, 'grade': 'F', 'interpretation': '성장 정체'}}, 'quality_analysis': {'quality_score': 1.0, 'quality_grade': 'A', 'completeness': {'rate': 100.0, 'available_indicators': 6, 'total_indicators': 6, 'grade': 'A'}, 'consistency': {'score': 1.0, 'grade': 'A'}, 'latest_update': '2022.12'}}, integrated_analysis={'symbol': '000660', 'analysis_timestamp': '2025-09-21T16:46:17.856491', 'opinion_analysis': {'symbol': '000660', 'analysis_period': '30일', 'total_opinions': 6, 'status': 'success', 'summary': InvestmentOpinionSummary(symbol='000660', total_opinions=6, buy_opinions=6, hold_opinions=0, sell_opinions=0, avg_target_price=411666.67, max_target_price=480000.0, min_target_price=380000.0, avg_upside=25.27, most_recent_date='20250918', opinion_trend='상향'), 'detailed_analysis': {'opinion_distribution': {'BUY': 4, '매수': 2}, 'daily_opinion_count': {'20250918': 1, '20250917': 2, '20250916': 1, '20250915': 1, '20250910': 1}, 'recent_changes': 0, 'most_active_date': '20250918', 'total_brokerages': 6}, 'trend_analysis': {'sentiment_trend': '보합', 'target_price_trend': '상승', 'opinion_change_frequency': 0.0}, 'consensus_analysis': {'consensus_score': 1.0, 'consensus_level': '강한 매수', 'sample_size': 6}, 'target_price_analysis': {'avg_target_price': 411666.67, 'max_target_price': 480000.0, 'min_target_price': 380000.0, 'price_range': 100000.0, 'avg_upside_potential': 42.94, 'target_count': 6, 'coverage_rate': 100.0}, 'brokerage_analysis': {'total_brokerages': 6, 'top_brokerages': [('대신', 1), ('SK', 1), ('현대차', 1), ('NH투자', 1), ('IM증권', 1)], 'brokerage_avg_targets': {'대신': 400000.0, 'SK': 480000.0, '현대차': 405000.0, 'NH투자': 395000.0, 'IM증권': 380000.0, '한국투자': 410000.0}, 'concentration_ratio': 16.666666666666664}}, 'estimate_analysis': {'symbol': '000660', 'status': 'success', 'summary': EstimatePerformanceSummary(symbol='A000660', name='에스케이하이닉스', current_price=0.0, change_rate=0.0, latest_revenue=446216.0, latest_revenue_growth=38.0, latest_operating_profit=68094.0, latest_operating_profit_growth=-451.0, latest_net_profit=22296.0, latest_net_profit_growth=-768.0, latest_eps=32420.0, latest_per=231.0, latest_roe=36.0, latest_ev_ebitda=34.0, revenue_trend='상승', profit_trend='상승', eps_trend='상승', data_quality_score=1.0, latest_update_date='2022.12'), 'detailed_analysis': {'data_completeness': {'rate': 100.0, 'available_indicators': 6, 'total_indicators': 6, 'grade': 'A'}, 'revenue_analysis': {'latest_value': 446216.0, 'growth_rate': 38.0, 'data_points': 5}, 'profit_analysis': {'operating_profit': 68094.0, 'net_profit': 22296.0, 'operating_growth': -451.0, 'net_growth': -768.0}, 'investment_metrics': {'eps': 32420.0, 'per': 231.0, 'roe': 36.0, 'ev_ebitda': 34.0, 'debt_ratio': 641.0, 'interest_coverage': 128.0}, 'settlement_periods': ['2022.12', '2023.12', '2024.12', '2025.12E', '2026.12E']}, 'trend_analysis': {'revenue': {'direction': '상승', 'strength': 15.156869036950294, 'volatility': 41.6085084543022, 'data_points': 5}, 'operating_profit': {'direction': '상승', 'strength': 23.23441192873568, 'volatility': 95.49386740240358, 'data_points': 5}, 'net_profit': {'direction': '상승', 'strength': 19.532238871256336, 'volatility': 108.20659300130065, 'data_points': 5}, 'eps': {'direction': '상승', 'strength': 19.591764946356165, 'volatility': 108.21088773168226, 'data_points': 5}, 'roe': {'direction': '상승', 'strength': 34.47037701974865, 'volatility': 113.04619349020601, 'data_points': 5}}, 'financial_health': {'health_score': 50, 'health_grade': 'C', 'factors': ['ROE 우수 (36.0%)', '부채비율 높음 (641.0%)', '이자보상배율 우수 (128.0배)'], 'max_score': 100}, 'valuation_analysis': {'per': {'value': 231.0, 'grade': 'F', 'interpretation': '매우 고평가'}, 'ev_ebitda': {'value': 34.0, 'grade': 'F', 'interpretation': '매우 고평가'}, 'overall_score': 10, 'overall_grade': 'F'}, 'growth_analysis': {'revenue_growth': {'value': 38.0, 'grade': 'A', 'interpretation': '매우 높은 성장'}, 'profit_growth': {'value': -451.0, 'grade': 'F', 'interpretation': '성장 정체'}, 'eps_growth': {'value': -768.0, 'grade': 'F', 'interpretation': '성장 정체'}}, 'quality_analysis': {'quality_score': 1.0, 'quality_grade': 'A', 'completeness': {'rate': 100.0, 'available_indicators': 6, 'total_indicators': 6, 'grade': 'A'}, 'consistency': {'score': 1.0, 'grade': 'A'}, 'latest_update': '2022.12'}}, 'integrated_score': 72.0, 'integrated_grade': 'B', 'investment_recommendation': '적극 검토 추천', 'risk_assessment': '낮음', 'total_opinions': 6, 'buy_opinions': 6, 'hold_opinions': 0, 'sell_opinions': 0, 'consensus_score': 1.0, 'avg_target_price': 411666.67, 'avg_upside': 25.27, 'opinion_trend': '상향', 'current_price': 0.0, 'latest_revenue': 446216.0, 'latest_revenue_growth': 38.0, 'latest_operating_profit': 68094.0, 'latest_operating_profit_growth': -451.0, 'latest_eps': 32420.0, 'latest_per': 231.0, 'latest_roe': 36.0, 'revenue_trend': '상승', 'profit_trend': '상승', 'eps_trend': '상승', 'data_quality_score': 1.0, 'financial_health_score': 50, 'valuation_score': 10}, risk_analysis={}, score_breakdown={'투자의견': 0.0, '추정실적': 0.0, '재무비율': 27.064285714285717, '성장성': 10.0, '규모': 5.0, '가격위치': -15.0}, error=None, price_data={'current_price': 353000.0, 'price_change': 0.0, 'price_change_rate': 0.0, 'volume': 4385543.0, 'per': 12.99, 'pbr': 3.38, 'eps': 27182.0, 'bps': 104567.0, 'market_cap': 256984800000000.0, 'w52_high': 360000.0, 'w52_low': 144700.0})"
    }
  ],
  "sector_analysis": {
    "기술업": {
      "count": 2,
      "total_score": 41.35000000000001,
      "avg_score": 20.675000000000004,
      "recommendations": {
        "BUY": 0,
        "HOLD": 2,
        "SELL": 0
      }
    },
    "바이오/제약": {
      "count": 1,
      "total_score": 34.832142857142856,
      "avg_score": 34.832142857142856,
      "recommendations": {
        "BUY": 0,
        "HOLD": 1,
        "SELL": 0
      }
    },
    "기타": {
      "count": 2,
      "total_score": 31.41785714285714,
      "avg_score": 15.70892857142857,
      "recommendations": {
        "BUY": 0,
        "HOLD": 2,
        "SELL": 0
      }
    }
  },
  "market_statistics": {
    "total_analyzed": 5,
    "avg_score": 21.52,
    "max_score": 34.832142857142856,
    "min_score": 14.285714285714288,
    "score_distribution": {
      "A+": 0,
      "A": 0,
      "B+": 0,
      "B": 0,
      "C": 0,
      "D": 2,
      "F": 3
    },
    "market_cap_stats": {
      "total_market_cap": 9424559.0,
      "avg_market_cap": 1884911.8,
      "max_market_cap": 4765308.0,
      "min_market_cap": 527493.0
    }
  }
}